BTIG raised the firm’s price target on Jade Biosciences (JBIO) to $39 from $28 and keeps a Buy rating on the shares. The firm is positive on the company’s potential in stepping into a large market opportunity in IgAN with their APRIL inhibitor JADE101 and Phase 1 healthy volunteer data expected in Q2, which could serve as an early confirmation of preferred positioning in what is materializing to be a booming commercial space, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JBIO:
- Jade Biosciences price target raised to $23 from $17 at Guggenheim
- Jade: Differentiated IgAN Profile and Multi-Asset Upside Make $2B Peak Sales for JADE101 Look Conservative
- Positioning Jade Biosciences as a Leading APRIL Inhibitor Play in IgA Nephropathy With Compelling Pipeline and Risk‑Reward
- Jade Biosciences price target raised to $40 from $19 at Stifel
- Jade Biosciences initiated with an Outperform at LifeSci Capital